Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
Status:
Terminated
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
Purpose: The investigators are proposing to examine the use of Savella® (Milnacipran) for
treating irritable bowel syndrome (IBS) in women.
Participants: Eligible participants will meet the Rome III diagnostic criteria for IBS.
Procedures: This study will observe patients treated with Savella® as well as patients
treated with a placebo (pill with no active drug). The investigators will monitor and compare
several patient and symptom related outcomes, as well as evaluate health related quality of
life, psychological distress and related psychosocial measures to determine if the addition
of Savella® improves clinical pain response as well as secondary outcomes including quality
of life.